cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Veracyte Inc
3 own
6 watching
Current Price
$20.23
$-0.5
(-2.41%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,874.72M
52-Week High
52-Week High
30.52000
52-Week Low
52-Week Low
19.52000
Average Volume
Average Volume
0.54M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,874.72M
icon52-Week High30.52000
icon52-Week Low19.52000
iconAverage Volume0.54M
iconDividend Yield--
iconP/E Ratio--
What does the Veracyte Inc do?
Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More
How much money does Veracyte Inc make?
News & Events about Veracyte Inc.
Business Wire
10 months ago
Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting new data on the companys Afirma test and capabilities will be presented at ENDO 2023, the annual meeting of The Endocrine Society, which is taking place June 15-18 in Chicago, Ill. Additionally, Veracytes medical...
Business Wire
11 months ago
Veracyte, Inc. (Nasdaq: VCYT) announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodules deemed indeterminate by cytopathology are rare, but have a high risk of malignancy and, in certain cases, are associated with aggressive...
Business Wire
11 months ago
Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report. The 2023 ESG Report sets the foundation for Veracytes ESG performance and outlines the companys ambitions to build upon its progress in the years ahead. As our company has...
Business Wire
12 months ago
Veracyte, Inc. (Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease (difficult-to-detect tumor cells that extend beyond the prostate) and who may...
Business Wire
1 year ago
Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the companys Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago. The...
Frequently Asked Questions
Frequently Asked Questions
What is Veracyte Inc share price today?
plus_minus_icon
Can Indians buy Veracyte Inc shares?
plus_minus_icon
How can I buy Veracyte Inc shares from India?
plus_minus_icon
Can Fractional shares of Veracyte Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Veracyte Inc stocks?
plus_minus_icon
What is today’s traded volume of Veracyte Inc?
plus_minus_icon
What is today’s market capitalisation of Veracyte Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Veracyte Inc?
plus_minus_icon
What percentage is Veracyte Inc down from its 52-Week High?
plus_minus_icon
What percentage is Veracyte Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$20.23
$-0.5
(-2.41%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00